Cleveland Diagnostics, a biotechnology company based in Cleveland, Ohio, has raised $75 million in funding. The financing round was led by Novo Holdings, with participation from existing investors and a credit facility from Symbiotic Capital. The funds will be used to accelerate the commercial strategy of IsoPSA, support expanded infrastructure and research and development pipeline development, and broaden the geographic scope of its IsoPSA prostate cancer test. Cleveland Diagnostics utilizes Solvent Interaction Analysis™ (SIA) technology to investigate protein biomarkers at the structure level for the early detection of cancers.